THE JOHNS HOPKINS MEDICAL INSTITUTIONS
Gallbladder and Bile Duct Cancer Web
Discussion BoardGleevec - tech. question was posted 05/11/2001 03:24 pm by Elizabeth W.
E-mail Address: email@example.com
Gleevec (STI571) for chronic myeloid leukemia has been approved. ABCNews.com
says it stops the activity of the abnormal protein, BCR-ABL, that is made by
the leukemia cells for proliferation. The article says that the new drug is
being tried on several solid tumor cancers. Is the abnormal protein,
BCR-ABL, expressed by other solid tumors or can Gleevec stop some other
abnormal proteins? And most importantly, can a distal common bile duct tumor
that is formulin(sp?)-fixed be tested for these molecular characteristics
(abnormal proteins)? Thanks. Elizabeth W.
Reply to this message |
Return to Main Message List
DISCLAIMER: This page is an unmoderated forum, and the opinions expressed herein do not necessarily reflect the viewpoint of The Johns Hopkins Medical Institutions.Patients are advised to consult their personal physicians before making any medical decisions.
Biliary Ca Home | Feedback | Pathology Home | Oncology Center Home Copyright © 2020 The Johns Hopkins University, Baltimore, MarylandLast Modified: 11/11/2002 10:50 am